Lakemore Partners Closes Fourth CLO Control Equity Investment Fund
CLO investor Lakemore Partners has closed its fourth CLO fund, Aquatine IV, at US$400mn.
Aquatine IV will invests in control equity positions in U.S. CLOs, and is currently one of the market’s largest dedicated CLO control equity funds. The fund’s investors are a diverse group of institutional investors representing private banks, fund of funds, insurance companies, family offices and high net worth individuals, many of whom have invested in previous Lakemore Aquatine Funds.
“The successful close of our Aquatine IV fund is an important milestone for Lakemore as we further strengthen our position as a global leader in CLO investments focused on delivering high risk-adjusted returns across market cycles,” said Mohamed Seif, Co-Founder & Managing Director of Lakemore.
“The significant interest and commitment to Aquatine IV highlights the trust and support our clients place in us,” added Hisham Ghouth, Partner and Head of Business Development. “Our investors recognize our long-standing partnerships with top-tier CLO managers, and we continue to experience strong demand from a range of global clients looking to access reliable and defensively managed credit portfolios.”
“Our team continues to deliver outstanding deal execution in 2021 through our involvement in more than 10 control equity transactions representing over US$6 billion in CLO size,” said Somnath Mukherjee, Partner and Head of Investments. “We would like to thank our collateral managers and arranging banks for their partnership in helping us to secure a robust pipeline during an incredibly active year, and for contributing to long-term, sustainable value for investors in our Aquatine Funds.”
© The Sortino Group Ltd
All Rights Reserved. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or scanning or otherwise, except under the terms of the Copyright, Designs and Patents Act 1988 or under the terms of a licence issued by the Copyright Licensing Agency or other Reprographic Rights Organisation, without the written permission of the publisher. For more information about reprints from AlphaWeek, click here.